Sparsentan in immunoglobulin A nephropathy: a profile of its use
Funding The preparation of this review was not supported by any external funding. Authorship and conflict of interest Young-A Heo, a salaried employee of Adis International Ltd/Springer Nature and an editor of Drugs & Therapy Perspectives, and ...
Connie Kang (7248215) +1 more
core +1 more source
Haematuria-Guided Therapy in Immunoglobulin A Nephropathy: From Biological Activity to Treatment Selection. [PDF]
Nephrology (Carlton)Wang Z, Lu Y.
europepmc +1 more source
Measuring effectiveness in immunoglobulin A nephropathy: what are we looking for? [PDF]
Clin Kidney JBarratt J +6 more
europepmc +1 more source
Remission of hematuria is associated with a better prognosis in immunoglobulin A nephropathy. [PDF]
Kidney Res Clin PractPark GN +7 more
europepmc +1 more source
Sparsentan for the Treatment of Immunoglobulin A Nephropathy: An Innovative Concept for Economic Modelling. [PDF]
J Clin MedBaxter G +2 more
europepmc +1 more source
Targeted release of budesonide modulates key gut microbial abnormalities in immunoglobulin A nephropathy. [PDF]
Front ImmunolMao X, Shang D, Chang S, Yang H, Lai L.
europepmc +1 more source
Evolving therapeutic landscape of immunoglobulin A nephropathy: targeted immune pathways and novel therapies. [PDF]
Kidney Res Clin PractKim Y.
europepmc +1 more source
The clinical value of metabolic indicators in immunoglobulin A nephropathy. [PDF]
Front Med (Lausanne)Zhao L, Zhang T, Zhou X.
europepmc +1 more source
Prognostic value of vascular lesions in immunoglobulin a nephropathy: a meta-analysis. [PDF]
BMC NephrolLei Z, Xu Y, Guo L, Liu Y, Zeng J, Lv J.
europepmc +1 more source